UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
__________________
FORM
8-K
__________________
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) April 27, 2005
__________________
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
__________________
| |
|
|
|
|
|
Delaware |
|
001-32177 |
|
22-2407152 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File No.) |
|
(I.R.S.
Employer
Identification
No.)
|
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item
8.01. Other Events
On April
27, 2005, NovaDel Pharma Inc. (the “Company”), issued a press release to
announce positive results from a pilot pharmacokinetic (PK) trial in healthy
human subjects. The trial was conducted using the Company’s proprietary lingual
spray technology to deliver alprazolam, the active ingredient marketed by Pfizer
as Xanax® for the
treatment of anxiety. The full text of the press release is set forth in Exhibit
99.1 hereto.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
99.1.
Press release dated April 27, 2005, titled “NovaDel
Pharma Announces Positive Pharmacokinetic Study Results for Alprazolam Lingual
Spray.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
NovaDel
Pharma Inc.
By:
/s/ Jean
W. Frydman
Name:
Jean W. Frydman
Title:
Vice President and General Counsel
Date:
April 28, 2005
EXHIBIT
INDEX
|
Exhibit |
|
Description |
|
99.1 |
|
Press
release dated April 27, 2005, titled “NovaDel
Pharma Announces Positive Pharmacokinetic Study Results for Alprazolam
Lingual Spray.” |